Antibody drug cuts moderate Alzheimer's decline, Swiss biotech cautions over results [FOX News]
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: FOX News
A Phase 2 trial involving an investigational monoclonal antibody drug, semorinemab, targeting the tau protein, reduced cognitive decline among adults with mild-to-moderate Alzheimer's disease by about 44%, Swiss biotech AC Immune announced Tuesday. Findings from the placebo-controlled study Lauriet stemmed from 272 adults with mild-to-moderate Alzheimer's disease across 43 study sites worldwide. Results indicated the drug, developed by Genentech (member of the Roche Group) resulted in a "statistically significant reduction in cognitive decline" by 43.6% at week 49, however the drug failed to slow the rate of functional decline or meet other efficacy endpoints. The drug was suggested to be safe and well-tolerated, without unanticipated safety signals, according to a company release posted Tuesday. The tau protein is one several factors believed to contribute to Alzheimer's disease when it aggregates into toxic tangles, which can damage cells and kill neurons. The antibody drug sem
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- Further weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58% [Yahoo! Finance]Yahoo! Finance
- AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]Yahoo! Finance
- AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateGlobeNewswire
- AC Immune Announces Upcoming Presentations at AD/PD™ 2024 [Yahoo! Finance]Yahoo! Finance
ACIU
Earnings
- 11/3/23 - Miss
ACIU
Sec Filings
- 3/14/24 - Form F-3
- 3/14/24 - Form 6-K
- 3/14/24 - Form 20-F
- ACIU's page on the SEC website